NDA 201023 · Sanofi Aventis US
Jevtana Kit
Cabazitaxel · Intravenous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jul 7, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Jun 17, 2010
Approved uses
4
Original approval plus efficacy supplements
Registered trials
127
21 Phase 3, 14 recruiting
FAERS reports
3,517
3,036 serious, 705 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NEUTROPENIA AND HYPERSENSITIVITY WARNING: NEUTROPENIA AND HYPERSENSITIVITY See full prescribing information for complete boxed warning. Neutropenic deaths have been reported. Obtain frequent blood counts to monitor for neutropenia. JEVTANA is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm 3 . Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Consider primary prophylaxis with G-CSF in all patients receiving a dose of 25 mg/m 2 ( 4 , 5.1 , 5.2 ) Severe hypersensitivity can occur and may include generalized rash/erythema, hypotension and bronchospasm. Discontinue JEVTANA immediately if severe reactions occur and administer appropriate therapy. ( 2.1 , 5.2 ) Contraindicated if history of severe hypersensitivity reactions to cabazitaxel or to drugs formulated with polysorbate 80. ( 4 ) Neutropenia : Neutropenic deaths...
What it is approved for
From the label in effect Oct 7, 2025.
JEVTANA ® is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. JEVTANA is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. ( 1 )
Mechanism: Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2020 Supplement 24 · Efficacy · priority review LetterLabel
- Sep 14, 2017 Supplement 19 · Efficacy LabelLetter
- May 17, 2017 Supplement 20 · Efficacy · priority review LabelLetterPediatric Written Request
- Jun 17, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelSummary ReviewLetterLabel
1 products under this application
- JEVTANA KIT · CABAZITAXEL 60MG/1.5ML (40MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cabazitaxel" as an intervention, any sponsor and status, largest first.
- Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01308580 · 1,200 participants · Start Apr 2011 · Primary completion Aug 2015
Drug: Cabazitaxel (XRP6258); Prednisone (or Prednisolone) · For: Prostate Cancer
Sites: Muscle Shoals, Alabama; Hot Springs, Arkansas; Anaheim, California · 172 sites in all
- Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01308567 · 1,168 participants · Start May 5, 2011 · Primary completion Sep 2015
Drug: Cabazitaxel (XRP6258); Docetaxel (XRP6976) and 1 more · For: Prostate Cancer
Sites: Muscle Shoals, Alabama; Anaheim, California; Bakersfield, California · 167 sites in all
- Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing RegimenPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01254279 · 984 participants · Start Dec 2010 · Primary completion Dec 2014
Drug: CABAZITAXEL · For: Prostate Cancer Metastatic
Sites: Box Hill, Australia; Campbelltown, Australia; Camperdown, Australia · 165 sites in all
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPCPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06855277 · 940 participants (planned) · Start Jul 1, 2025 · Primary completion Sep 29, 2028
Drug: AAA817; ARPI and 1 more · For: Prostate Cancer
Sites: Homewood, Alabama; Tucson, Arizona; Orange, California · 106 sites in all
- A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of RelapsePivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT01952223 · 761 participants · Start Dec 2013 · Primary completion Dec 2025
Drug: Cabazitaxel · For: Adenocarcinoma of Prostate; Progression of Prostate Cancer
Sites: Villejuif, France
- XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00417079 · 755 participants · Start Jan 2007 · Primary completion Sep 2009
Drug: cabazitaxel (XRP6258) (RPR116258); mitoxantrone and 1 more · For: Neoplasms; Prostatic Neoplasms
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Diegem, Belgium · 26 sites in all
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPivotal-lookingRecruiting
Karolinska InstitutetAcademic, hospital or other
NCT03903835 · 750 participants (planned) · Start Feb 1, 2019 · Primary completion Dec 2026
Drug: Enzalutamide Oral Capsule; Abiraterone Oral Tablet and 8 more · For: Metastatic Castration-resistant Prostate Cancer (mCRPC); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Aalst, Belgium; Antwerp, Belgium; Bruges, Belgium · 32 sites in all
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07213674 · 750 participants (planned) · Start Nov 28, 2025 · Primary completion Jan 7, 2030
Drug: Xaluritamig; Abiraterone acetate and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Goodyear, Arizona; Tucson, Arizona; Duarte, California · 159 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- febrile neutropenia250
- malignant neoplasm progression238
- fatigue210
- prostatic specific antigen increased202
- diarrhoea191
- disease progression187
- anaemia180
- neutropenia174
- pyrexia172
- drug ineffective162
- death155
- asthenia139
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 6 |
| 2011 | 46 |
| 2012 | 162 |
| 2013 | 190 |
| 2014 | 237 |
| 2015 | 224 |
| 2016 | 207 |
| 2017 | 152 |
| 2018 | 267 |
| 2019 | 297 |
| 2020 | 264 |
| 2021 | 392 |
| 2022 | 283 |
| 2023 | 232 |
| 2024 | 193 |
| 2025 | 241 |
| 2026 | 124 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, et al. · Lancet 2021 · Clinical Trial, Phase II, Multicenter Study
- Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
Garje R, Riaz IB, Naqvi SAA, et al. · J Clin Oncol 2025 · Practice Guideline, Systematic Review
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit R, de Bono J, Sternberg CN, et al. · N Engl J Med 2019 · Comparative Study, Multicenter Study
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, et al. · Lancet 2010 · Clinical Trial, Phase III, Comparative Study
- PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau JP, Martin AJ, Emmett L, et al. · Lancet Oncol 2022 · Randomized Controlled Trial, Multicenter Study
- Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.
Soon YY, Marschner IC, Schou M, et al. · JAMA Netw Open 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.